MedPath

Continuous Glucose Monitoring for Glucose and Weight Management in Prediabetes and Non-severe Type 2 Diabetes: A Prospective Community-based (Workplace) Cohort Study

Not Applicable
Recruiting
Conditions
PreDiabetes
Diabetes Mellitus, Type 2
Interventions
Device: Freestyle Libre
Registration Number
NCT06542627
Lead Sponsor
Kangbuk Samsung Hospital
Brief Summary

This study aimed to evaluate the effectiveness of use of Continuous Glucose Monitoring (CGM), combined with personalized dietary education and use of smartphone applications in improving glucose control and weight management.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
420
Inclusion Criteria
  • Subjects over the age of 19

  • Patients with type 2 diabetes

    • Fasting blood glucose ≥ 126 mg/dL or
    • HbA1c ≥ 6.5% or
    • Type 2 diabetes by clinical history and treated with antidiabetic medications or lifestyle Modifications
  • Patients with prediabetes

    • Fasting blood glucose 100-125 mg/dL
    • HbA1c 5.7-6.4%
  • Willing to participate in the study

Exclusion Criteria
  • Subjects less than 19 years old
  • Patients with type 1 diabetes
  • Pregnant at the time of screening or planning to become pregnant during the study
  • Severe chronic diseases such as cancer, stroke, proliferative retinopathy, myocardial infarction, chronic renal disease, or amputation of a diabetic foot
  • Diagnosed with or treated for myocardial infarction, stroke, end-stage renal disease, liver failure, or chronic lung disease within the past year
  • Severe liver disease (e.g., cancer, liver cirrhosis, hepatitis B, hepatitis C)
  • Diseases of the biliary tract, thyroid disorders, autoimmune disorders, or acute infections
  • Planning to be admitted to a hospital within 2 months
  • Unable to participate in the mobile intervention study as determined by the investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CGM armFreestyle LibreGlycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
Primary Outcome Measures
NameTimeMethod
HbA1c8weeks after intervention

HbA1c assessed by blood test after 2-week use of CGM and dietary education

Secondary Outcome Measures
NameTimeMethod
Fasting blood glucose8weeks after intervention

Fasting blood glucose, assessed by blood test after 2-week use of CGM and dietary education

Pre- and post-intervention questionnaire: Diabetes Treatment Satisfaction Questionnaire (DTSQ)8weeks after intervention

Pre- and post-intervention questionnaires, assessed by self-reported survey. The questionnaire is composed of three parts.

* total satisfaction (minimum 0, maximum 36, higher scores mean a better outcome.)

* perceived hyperglycaemia (minimum 0, maximum 6, higher scores mean a worse outcome.)

* perceived hypoglycaemia (minimum 0, maximum 6, higher scores mean a worse outcome.)

Pre- and post-intervention questionnaire: Summary of Diabetes Self-Care Activities Questionnaire (SDSCAS).8weeks after intervention

Pre- and post-intervention questionnaires, assessed by self-reported survey. The questionnaire is composed of five parts.

* diet (values: minimum 0, maximum 28, higher scores mean a better outcome.)

* exercise (minimum 0, maximum 14, higher scores mean a better outcome.)

* blood sugar check-up (values: minimum 0, maximum 14, higher scores mean a better outcome.)

* foot care (minimum 0, maximum 14, higher scores mean a better outcome.)

* smoking (minimum 0, maximum 1, higher scores mean a worse outcome.)

Body weight8weeks after intervention

Body weight assessed by blood test after 2-week use of CGM and dietary education

Lipid profiles8weeks after intervention

Lipid profiles (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride), assessed by blood test after 2-week use of CGM and dietary education

Trial Locations

Locations (1)

Kangbuk Samsung Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath